Pathophysiology of Heart Failure

作者: Johannes Mair

DOI: 10.1007/978-1-59259-385-9_22

关键词:

摘要: Heart failure (HF) has become a public health issue that is so important it been named “new epidemic of cardiovascular disease,” and its prognosis poor. The 5-yr mortality rate in patients with mild HF approx 50%; the annual mortalities depend on disease severity range from <5% asymptomatic to 30–80% endstage disease, 10% 20–30% moderate (1). Today, single most frequent cause hospitalization persons 65 yr age or older becomes more common increasing age. increase aging population growing number people surviving myocardial infarctions are reasons why prevalence rising steadily. Fortunately, during last three decades substantial improvements diagnosis, management, treatment have achieved. Drugs available demonstrated unequivocally delay death, enable avoid hospitalization, improve quality life assessed by exercise capacity symptoms questionnaires. In 1970s was perceived as were closely allied hemodynamic disequilibrium. This model suggested increased ventricular wall stress principal HF. It thought these abnormalities can be rectified use vasodilating drugs lead afterload reduction. These fact lowered left atrial pressure cardiac output, acute rapidly improved such diuretics, vasodilators, morphine. response relates largely changes central hemodynamics. However, soon realized administration some afterload-reducing not associated any clinical benefit patients’ outcomes even after improvement status had origin chronic (CHF) related simple manner findings well (2). discoveries led for­mulation neurohormonal hypothesis progression (3). recent years much learned about pathophysiology HF, today regarded disorder due impaired pump function reduced output subsequent venous congestion. Complex activation aimed at improv­ing mechanical environment heart, circulating local hormones proinflammatory cytokines play an role progression. fact, developments intro­duction first angiotensin converting enzyme (ACE) inhibitors then s-blockers, which resulted almost 50% decrease decade therapeutic trials. great benefits delaying mainly attributable their neurohumoral effects beneficial remodeling failing heart. chapter focuses complex diagnostic implications.

参考文章(32)
G Sagnella, Atrial natriuretic peptide mimetics and vasopeptidase inhibitors. Cardiovascular Research. ,vol. 51, pp. 416- 428 ,(2001) , 10.1016/S0008-6363(01)00289-9
Gerd Hasenfuss, Alterations of calcium-regulatory proteins in heart failure Cardiovascular Research. ,vol. 37, pp. 279- 289 ,(1998) , 10.1016/S0008-6363(97)00277-0
Johannes Mair, Angelika Hammerer-Lercher, Bernd Puschendorf, The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clinical Chemistry and Laboratory Medicine. ,vol. 39, pp. 571- 588 ,(2001) , 10.1515/CCLM.2001.093
L A Mulieri, G Hasenfuss, B Leavitt, P D Allen, N R Alpert, Altered myocardial force-frequency relation in human heart failure. Circulation. ,vol. 85, pp. 1743- 1750 ,(1992) , 10.1161/01.CIR.85.5.1743
A.J. de Bold, H.B. Borenstein, A.T. Veress, H. Sonnenberg, A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats Life Sciences. ,vol. 28, pp. 89- 94 ,(1981) , 10.1016/0024-3205(81)90370-2
E Braunwald, Congestive heart failure: a half century perspective European Heart Journal. ,vol. 22, pp. 825- 836 ,(2001) , 10.1053/EUHJ.2001.2614
Karl Swedberg, Peter Eneroth, John Kjekshus, Steve Snapinn, The CONSENSUS Trial Study Groupabcd, Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial) American Journal of Cardiology. ,vol. 66, ,(1990) , 10.1016/0002-9149(90)90475-G